Questions, answered from the record
Kisspeptin questions, answered from the published literature.
The isoform difference, the half-lives, the testosterone and fertility data, and the desensitization problem — each answer direct and cited.
What is the difference between kisspeptin-10 and kisspeptin-54?
Length and duration. Kisspeptin-10 is the ten-residue fragment (about 1302.5 Da, ~4-minute half-life); kisspeptin-54 is the fifty-four-residue isoform (about 5857 Da, ~27.6-minute half-life) [8]. Both end in the same receptor-binding tail and point the same direction — at matched infusion rates in men they give comparable acute gonadotropin responses — so the practical difference is that KP-54 sustains its signal far longer [9].
What is the half-life of kisspeptin?
It depends on the isoform. Kisspeptin-54 has a measured human plasma half-life of 27.6 ± 1.1 minutes [8], while kisspeptin-10 lasts only about 4 minutes because plasma peptidases clear the short fragment quickly [3]. The larger KP-54 resists enzymatic cleavage better, which is why it reaches higher peaks and acts longer than KP-10 at equal doses [11].
Why does kisspeptin-54 produce longer-lasting LH release than kisspeptin-10?
Because it survives longer in the blood. Mechanistic work attributes KP-54's higher peak levels and more sustained LH release directly to its greater resistance to peptidase cleavage, and reports it also activates central GnRH neurons more effectively [11]. The intact fifty-four-residue peptide is degraded more slowly than the ten-residue fragment, so its signal persists — a 27.6-minute half-life versus about 4 minutes [8].
Does repeated kisspeptin dosing cause desensitization of the GPR54 receptor?
Yes — this is the defining limitation. Twice-daily subcutaneous kisspeptin-54 in women with hypothalamic amenorrhea caused the acute LH response to fall from about 24 IU/L on day 1 to roughly 2.5 IU/L by the fourteenth injection day [10]. High-dose continuous IV infusion likewise desensitized the axis during the infusion [4]. Sustained or frequent KISS1R activation downregulates the receptor, so continuous dosing tends to defeat itself.
What is the plasma half-life of kisspeptin-10 compared to kisspeptin-54?
Kisspeptin-10 clears in roughly 4 minutes; kisspeptin-54 lasts about 27.6 ± 1.1 minutes — close to a sevenfold difference [3][8]. The gap reflects size and enzymatic stability: the short fragment is rapidly cut by plasma peptidases, while the larger peptide resists cleavage and sustains its action far longer [11].
What is kisspeptin?
Kisspeptin is the KISS1-gene neuropeptide that sits at the top of the reproductive hormone axis — a KISS1R (GPR54) agonist that stimulates hypothalamic GnRH neurons, which in turn drive LH and FSH and the sex steroids [1]. The proof of its importance is genetic: people with loss-of-function GPR54 mutations fail to enter puberty, and knockout mice reproduce that phenotype [1]. It is not a sex hormone itself — it is the upstream switch.
What does kisspeptin do?
It wakes the reproductive axis. Kisspeptin binds KISS1R on GnRH neurons and depolarizes them — raising firing rate by about 87 ± 4% in adult GnRH neurons in one study — which triggers pulsatile GnRH release, then LH and FSH from the pituitary, then the gonadal sex steroids [2]. It is the master upstream signal; without working kisspeptin–GPR54 signaling, puberty does not start [1].
Does kisspeptin increase testosterone?
In studies of healthy men, yes — indirectly, by raising LH. Intravenous kisspeptin-10 at a higher 4 µg/kg/h infusion raised serum testosterone from 16.6 to 24.0 nmol/L, downstream of its LH stimulation [3]. Kisspeptin does not supply testosterone; it drives the LH signal that tells the testes to make it. This is research data in a supervised setting, not a dosing recommendation.
How much does kisspeptin increase testosterone?
One study in healthy men reported serum testosterone rising from 16.6 to 24.0 nmol/L under a continuous IV kisspeptin-10 infusion at 4 µg/kg/h — about a 45% increase from baseline [3]. The same study's lower doses primarily raised LH and pulse frequency; the testosterone rise followed the stronger LH stimulation [3]. These are research figures, attributed to a defined population and route, not a personal target.
What is kisspeptin used for in research?
It is studied as a probe and a potential tool for the reproductive axis. A 2025 systematic review mapped 29 interventional trials across secondary amenorrhea, regulation of puberty onset, ovarian function, trophoblast invasion, fertility regulation, parturition and lactation [7]. The genetics that opened the field showed kisspeptin–GPR54 signaling is essential for reproductive maturation [1]. No use is regulatory-approved.
Can kisspeptin help with fertility?
In research, it has shown clear fertility-relevant effects. A Phase 2 trial used subcutaneous kisspeptin-54 (3.2–12.8 nmol/kg) to trigger oocyte maturation in 95% of high-OHSS-risk IVF patients with no case of moderate-to-critical OHSS, and a 9.6 nmol/kg dose gave the highest live-birth rate (62%) [5]. It remains investigational and is not an approved fertility treatment.
Can kisspeptin restore ovulation in women with hypothalamic amenorrhea?
In supervised studies it restored the LH pulsatility that ovulation depends on. Continuous IV kisspeptin-54 (0.01–1.00 nmol/kg/h) raised LH pulses from 1.6 to 5.0 per 8 hours (about threefold) and pulse secretory mass roughly sixfold versus vehicle in women with hypothalamic amenorrhea, though the highest dose caused tachyphylaxis [4]. This is investigational research, not an approved therapy.
What is the KISS1 gene?
KISS1 (on chromosome 1q32) is the gene that encodes the kisspeptin family. It was discovered in 1996 as a metastasis-suppressor gene, and its product was only later recognized as the upstream activator of GnRH neurons [1]. Loss-of-function mutations in its receptor, GPR54 (KISS1R), cause failure of puberty — the finding that established the gene's role in reproduction [1].
What is metastin and how does it relate to kisspeptin?
Metastin is the original name for kisspeptin-54. When KISS1 was identified as a metastasis-suppressor gene, its fifty-four-residue product was named metastin; the same molecule is now usually called kisspeptin-54 [1]. So metastin and KP-54 are interchangeable names for the longer isoform — the one with the ~28-minute half-life used in most clinical studies [8].
How was kisspeptin discovered?
Twice over, in effect. KISS1 was first found in 1996 as a metastasis-suppressor gene in human melanoma. Its true reproductive role emerged in 2003, when loss-of-function mutations in the receptor GPR54 were shown to cause hypogonadotropic hypogonadism and failure of puberty in humans, with knockout mice confirming it — recasting kisspeptin as the master upstream switch of the reproductive axis [1].
What receptor does kisspeptin bind?
Kisspeptin binds KISS1R, a Gq/11-coupled G-protein-coupled receptor formerly known as the orphan GPR54 (also hOT7T175 / AXOR12) [1]. The receptor is expressed on hypothalamic GnRH neurons; activating it fires the phospholipase-C / IP3 / calcium cascade that depolarizes the neuron and drives GnRH release [2]. Its essential role was proven by the puberty failure that follows loss-of-function GPR54 mutations [1].
How does kisspeptin work in the body?
It works from the top of the chain. Kisspeptin binds KISS1R on GnRH neurons and depolarizes them through a PLC / IP3 / intracellular-calcium cascade that closes potassium channels and opens cation channels [2]. That triggers pulsatile GnRH release, which drives LH and FSH from the pituitary, which drive the gonadal sex steroids [1]. KNDy neurons in the arcuate nucleus are thought to pace the underlying pulse [2].
How long does kisspeptin take to work?
Fast — minutes. In healthy men, intravenous kisspeptin-10 produced maximal LH stimulation at 30 minutes, lifting LH from 4.1 to 12.4 IU/L [3]. The 2025 intranasal kisspeptin-54 study likewise described rapid LH stimulation after dosing [6]. The hormonal response is quick; how long it lasts depends on the isoform's half-life — roughly 4 minutes for KP-10 versus ~28 minutes for KP-54 [8].
What is the mechanism by which kisspeptin-10 exerts its effects?
Kisspeptin-10 binds KISS1R on GnRH neurons and activates a phospholipase-C / IP3 / intracellular-calcium cascade; that closes potassium channels and opens non-selective cation channels, depolarizing the neuron — in one study raising firing rate by about 87 ± 4% — and driving pulsatile GnRH release [2]. The ten-residue fragment keeps the Arg-Phe-amide tail the receptor needs, so it retains full activity despite its small size [3].
How does stress suppress kisspeptin and disrupt the reproductive axis?
Through the same KNDy circuitry that normally drives it. A review of functional hypothalamic amenorrhea describes how psychological stress, disordered eating, low body weight and excessive exercise suppress GnRH pulsatility and lower LH and estradiol, with KNDy (kisspeptin / neurokinin B / dynorphin) neurons acting on GnRH neurons as central to this regulation [14]. When the kisspeptin signal quiets, the axis downstream of it quiets too — which is why restoring LH pulses with kisspeptin-54 has been studied in exactly this population [4].
How does kisspeptin reduce OHSS risk compared to hCG as an IVF trigger?
By triggering a more physiological, self-limiting hormone surge instead of a long-lasting one. In a Phase 2 trial of 60 high-OHSS-risk women, a subcutaneous kisspeptin-54 trigger (3.2–12.8 nmol/kg) matured oocytes in 95% of women with no case of moderate, severe or critical OHSS [5]. The trial framed kisspeptin-54 as a safer alternative trigger because it stimulates the body's own gonadotropin release rather than supplying a sustained external signal [5].
Can kisspeptin-54 trigger ovulation more safely than GnRH agonists in IVF?
The Phase 2 evidence points that way on safety. Subcutaneous kisspeptin-54 (3.2–12.8 nmol/kg) triggered oocyte maturation in 95% of high-risk women with no moderate-to-critical OHSS, and the 9.6 nmol/kg dose produced the highest live-birth rate (62%) [5]. Because kisspeptin acts one step upstream — driving the body's own GnRH and gonadotropin release — it was studied specifically as a gentler trigger; it remains investigational [5].